Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The management of membranous nephropathy—an update

Caravaca-Fontán, Fernando ; Fernández-Juárez, Gema M. ; Floege, Jürgen ; Goumenos, Dimitrios ; Kronbichler, Andreas ; Turkmen, Kultigin ; van Kooten, Cees ; Frangou, Eleni ; Stevens, Kate I. and Segelmark, Mårten LU , et al. (2022) In Nephrology Dialysis Transplantation 37(6). p.1033-1042
Abstract

In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in... (More)

In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
calcineurin inhibitors, cyclophosphamide, membranous nephropathy, remission, rituximab
in
Nephrology Dialysis Transplantation
volume
37
issue
6
pages
10 pages
publisher
Oxford University Press
external identifiers
  • pmid:34748001
  • scopus:85131018498
ISSN
0931-0509
DOI
10.1093/ndt/gfab316
language
English
LU publication?
yes
id
81735f57-f2e6-496c-b457-5eab602afc1a
date added to LUP
2022-12-29 11:12:09
date last changed
2024-04-04 15:07:44
@article{81735f57-f2e6-496c-b457-5eab602afc1a,
  abstract     = {{<p>In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.</p>}},
  author       = {{Caravaca-Fontán, Fernando and Fernández-Juárez, Gema M. and Floege, Jürgen and Goumenos, Dimitrios and Kronbichler, Andreas and Turkmen, Kultigin and van Kooten, Cees and Frangou, Eleni and Stevens, Kate I. and Segelmark, Mårten and Tesar, Vladimir and Anders, Hans Joachim and Bruchfeld, Annette}},
  issn         = {{0931-0509}},
  keywords     = {{calcineurin inhibitors; cyclophosphamide; membranous nephropathy; remission; rituximab}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{1033--1042}},
  publisher    = {{Oxford University Press}},
  series       = {{Nephrology Dialysis Transplantation}},
  title        = {{The management of membranous nephropathy—an update}},
  url          = {{http://dx.doi.org/10.1093/ndt/gfab316}},
  doi          = {{10.1093/ndt/gfab316}},
  volume       = {{37}},
  year         = {{2022}},
}